vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Neptune Insurance Holdings Inc. (NP). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $37.8M, roughly 1.0× Neptune Insurance Holdings Inc.). Neptune Insurance Holdings Inc. runs the higher net margin — 0.1% vs -161.8%, a 161.9% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 28.8%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Neptune Insurance Holdings Inc. is a specialty insurance holding company that offers a broad portfolio of property and casualty insurance products, with a core focus on residential and commercial flood insurance for customers across the United States. It serves both individual consumers and small to mid-sized business clients, using advanced data analytics to support accurate policy pricing and robust risk management.

IBRX vs NP — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.0× larger
IBRX
$38.3M
$37.8M
NP
Growing faster (revenue YoY)
IBRX
IBRX
+378.2% gap
IBRX
407.0%
28.8%
NP
Higher net margin
NP
NP
161.9% more per $
NP
0.1%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBRX
IBRX
NP
NP
Revenue
$38.3M
$37.8M
Net Profit
$-61.9M
$50.0K
Gross Margin
99.0%
Operating Margin
-169.0%
Net Margin
-161.8%
0.1%
Revenue YoY
407.0%
28.8%
Net Profit YoY
-4.7%
0.0%
EPS (diluted)
$-0.06
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
NP
NP
Q1 26
$37.8M
Q4 25
$38.3M
Q3 25
$32.1M
$44.4M
Q2 25
$26.4M
Q1 25
$16.5M
Q4 24
$7.6M
Q3 24
$6.1M
$33.8M
Net Profit
IBRX
IBRX
NP
NP
Q1 26
$50.0K
Q4 25
$-61.9M
Q3 25
$-67.3M
$11.5M
Q2 25
$-92.6M
Q1 25
$-129.6M
Q4 24
$-59.2M
Q3 24
$-85.7M
$12.1M
Gross Margin
IBRX
IBRX
NP
NP
Q1 26
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Operating Margin
IBRX
IBRX
NP
NP
Q1 26
Q4 25
-169.0%
Q3 25
-173.5%
46.7%
Q2 25
-269.8%
Q1 25
-390.1%
Q4 24
-919.0%
Q3 24
-1314.3%
58.6%
Net Margin
IBRX
IBRX
NP
NP
Q1 26
0.1%
Q4 25
-161.8%
Q3 25
-209.8%
25.9%
Q2 25
-350.3%
Q1 25
-784.9%
Q4 24
-783.4%
Q3 24
-1404.0%
35.8%
EPS (diluted)
IBRX
IBRX
NP
NP
Q1 26
$0.05
Q4 25
$-0.06
Q3 25
$-0.07
$0.06
Q2 25
$-0.10
Q1 25
$-0.15
Q4 24
$-0.08
Q3 24
$-0.14
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
NP
NP
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
Total Assets
$501.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
NP
NP
Q1 26
Q4 25
$242.8M
Q3 25
$257.8M
$12.2M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Total Debt
IBRX
IBRX
NP
NP
Q1 26
Q4 25
Q3 25
$247.6M
Q2 25
Q1 25
Q4 24
Q3 24
Stockholders' Equity
IBRX
IBRX
NP
NP
Q1 26
Q4 25
$-500.5M
Q3 25
$-524.3M
$-509.5M
Q2 25
$-570.7M
Q1 25
$-591.4M
Q4 24
$-489.1M
Q3 24
$-745.1M
$-374.3M
Total Assets
IBRX
IBRX
NP
NP
Q1 26
Q4 25
$501.9M
Q3 25
$519.0M
$89.6M
Q2 25
$402.1M
Q1 25
$303.8M
Q4 24
$382.9M
Q3 24
$364.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
NP
NP
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
NP
NP
Q1 26
Q4 25
$-70.4M
Q3 25
$-68.9M
$38.9M
Q2 25
$-79.7M
Q1 25
$-85.9M
Q4 24
$-85.1M
Q3 24
$-98.8M
Free Cash Flow
IBRX
IBRX
NP
NP
Q1 26
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
FCF Margin
IBRX
IBRX
NP
NP
Q1 26
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Capex Intensity
IBRX
IBRX
NP
NP
Q1 26
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Cash Conversion
IBRX
IBRX
NP
NP
Q1 26
Q4 25
Q3 25
3.38×
Q2 25
Q1 25
Q4 24
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons